Harvard Bioscience, Inc.
HBIO
$0.7753
$0.00140.18%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.97M | 23.10M | 24.51M | 28.15M | 25.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.97M | 23.10M | 24.51M | 28.15M | 25.36M |
| Cost of Revenue | 9.21M | 9.88M | 9.74M | 11.51M | 10.64M |
| Gross Profit | 12.77M | 13.22M | 14.77M | 16.65M | 14.73M |
| SG&A Expenses | 10.56M | 11.08M | 11.87M | 11.23M | 11.54M |
| Depreciation & Amortization | 1.33M | 1.33M | 1.33M | 1.39M | 1.36M |
| Other Operating Expenses | -- | -147.00K | 966.00K | -- | -- |
| Total Operating Expenses | 23.67M | 24.77M | 26.79M | 27.27M | 26.30M |
| Operating Income | -1.70M | -1.67M | -2.28M | 883.00K | -933.00K |
| Income Before Tax | -4.49M | -3.28M | -4.48M | -1.10M | -562.00K |
| Income Tax Expenses | 311.00K | -353.00K | 210.00K | 715.00K | 677.00K |
| Earnings from Continuing Operations | -4.80M | -2.93M | -4.69M | -1.82M | -1.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.80M | -2.93M | -4.69M | -1.82M | -1.24M |
| EBIT | -1.70M | -1.67M | -2.28M | 883.00K | -933.00K |
| EBITDA | 120.00K | 128.00K | -498.00K | 2.66M | 846.00K |
| EPS Basic | -0.11 | -0.07 | -0.11 | -0.04 | -0.03 |
| Normalized Basic EPS | -0.06 | -0.04 | -0.06 | 0.00 | -0.01 |
| EPS Diluted | -0.11 | -0.07 | -0.11 | -0.04 | -0.03 |
| Normalized Diluted EPS | -0.06 | -0.04 | -0.06 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 43.61M | 43.49M | 43.40M | 42.71M | 42.69M |
| Average Diluted Shares Outstanding | 43.61M | 43.49M | 43.40M | 42.71M | 42.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
